Investigation of Aberrant Translational Control of c-myc in Cell Lines Derived from Patients with Multiple Myeloma
In cell lines derived from patients with multiple myeloma (MM) we have found an elevation in the amount of the c-myc protein which is not accompanied by an increase in the level of mRNA or a change in the half-life of the protein. There is a 3.4 fold enhancement in the degree of association of the c-myc message with polysomes. This is not accompanied by an alteration in polysome size or a change in the transit time of the c-myc mRNA on the polysomes thus suggesting that there is an increase in the degree of mobilisation of the c-myc message. Sequencing of the c-myc 5’UTR has revealed the presence of a mutation in all the MM cell lines studied and we demonstrate that this mutation causes altered binding of cellular proteins to this RNA species.
KeywordsMultiple Myeloma Electrophoretic Mobility Shift Assay Mutant Sequence Control Cell Line Wild Type Sequence
Unable to display preview. Download preview PDF.
- Carter A, Merchav I, Silvian-Draxler I and Tatarsky I. (1990) The role of inerleukin-1 and tumour necrosis factor alpha in human multiple myeloma. Blood 74:424–431.Google Scholar
- Hiltzer J, Martinez-Valdez D, Berghasel M, Minden M and Messener H., (1991) Role of Interleukin-6 in the proliferation of human multiple myeloma cell lines oci-my 1 to 7 established from patients with advanced Stage of the disease. Blood 8:1996–2004.Google Scholar